Cimeio Therapeutics Company
Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders. The technology platform developed by Cimeio is based on the design and expression of modified variants of naturally occurring cell surface proteins in HSCs. The SCIP platform could allow more patients facing debilitating and fatal diseases to receive a life-saving HSC transplant. Its mission is to significantly improve the eligibility and outcomes of hematopoietic stem cell transplants and adoptive cell therapy.
Headquarters:
Basel, Basel-Stadt, Switzerland, Europe
Employee Number:
11-50
Industry:
Cell, Gene & Biologics Therapeutics
Founded Date:
2020-01-01
Super Industry:
Biopharma & Life Science Tools
Phone Number:
+41 61 577 2316
Investors:
Versant Ventures
Ipo Status:
private
City:
Basel
Region:
Basel-Stadt
Country:
Switzerland

